Filing Details

Accession Number:
0000899243-18-031493
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-12-20 19:04:00
Reporting Period:
2018-12-18
Accepted Time:
2018-12-20 19:04:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1422142 Aerpio Pharmaceuticals Inc. ARPO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1315797 A Muneer Satter C/O Aerpio Pharmaceuticals, Inc.
9987 Carver Road, Suite 420
Cincinnati OH 45242
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-12-18 20,000 $1.99 5,338,017 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-12-19 20,000 $1.92 5,358,017 No 4 P Indirect See footnote
Common Stock Acquisiton 2018-12-20 20,000 $1.85 5,378,017 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. All shares were purchased by Satter Medical Technology Partners, L.P.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $2.06. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  3. The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.81 to $2.06. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.